Acorn Capital Advisors’s Bicara Therapeutics BCAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.4M Buy
668,381
+25,000
+4% +$626K 3.42% 8
2026
Q2
$19.1M Sell
643,381
-1
-0% -$22 5.21% 7
2026
Q1
$12.8M Hold
643,382
– – 3.64% 7
2025
Q4
$10.8M Hold
643,382
– – 3.67% 9
2025
Q3
$10.2M Hold
643,382
– – 5.16% 7
2025
Q2
$5.98M Hold
643,382
– – 3.91% 10
2025
Q1
$8.38M Buy
643,382
+1
+0% +$13 5.59% 7
2024
Q4
$11.2M Buy
+643,381
New +$13.4M 6.03% 6

Other funds holding BCAX

Acorn Capital Advisors's BCAX Position: Q3 2026 in Review

Acorn Capital Advisors increased its Bicara Therapeutics (BCAX) stake by 3.9% in Q3 2026, buying an estimated $626K and bringing the position to 668,381 shares worth $12.4M. The position accounts for 3.42% of the portfolio, ranked #8.

Acorn Capital Advisors first reported a position in BCAX in Q4 2024 and has held it in 8 quarters since. The position peaked at $19.1M in Q2 2026. 169 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

  • Acorn Capital Advisors held 668,381 shares of Bicara Therapeutics worth $12.4M as of Q3 2026.
  • Acorn Capital Advisors bought 25,000 Bicara Therapeutics shares in Q3 2026, an estimated $626K.
  • Bicara Therapeutics made up 3.42% of Acorn Capital Advisors's portfolio in Q3 2026, its #8 holding.
  • Acorn Capital Advisors first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Acorn Capital Advisors's Bicara Therapeutics position peaked at $19.1M in Q2 2026.
  • 169 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on Acorn Capital Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.